Moving into the future: Treatment of bone metastases and beyond

Cancer Treatment Reviews

Volumn 31, Issue SUPPL. 3, 2005, Pages 9-18

  Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adjuvant therapy; Bisphosphonates; Bone; Bone mineral density; Breast cancer; Cancer treatment induced bone loss; Metastases; Patient autonomy; Prostate cancer; Quality of life; Zoledronic acid

Indexed keywords

ANASTROZOLE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; BUSERELIN; CALCIUM; CELECOXIB; CLODRONIC ACID; DOCETAXEL; DOXORUBICIN; EXEMESTANE; FLUTAMIDE; GONADORELIN; GONADORELIN AGONIST; GOSERELIN; IFOSFAMIDE; LETROZOLE; LEUPRORELIN; METHOTREXATE; NERIDRONIC ACID; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; TAMOXIFEN; TRIPTORELIN; UNINDEXED DRUG; VITAMIN D; ZOLEDRONIC ACID;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE DISEASE; BONE METASTASIS; BONE MINERAL; BREAST CANCER; CANCER STAGING; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FRACTURE; HORMONAL THERAPY; HUMAN; OSTEOLYSIS; OSTEOPENIA; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PROSTATE CANCER; QUALITY OF LIFE; RISK ASSESSMENT; SOLID TUMOR;

EID: 28844472096     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2005.09.003     Document Type: Article

References (44)

1. G.E. Friedlaender R.B. Tross A.C. Doganis J.M. Kirkwood R. Baron Effects of chemotherapeutic agents on bone. I. Short-term methotrexate and doxorubicin (adriamycin) treatment in a rat model J Bone Joint Surg Am 66 4 1984 602-607
2. P.D. Delmas A. Fontana Bone loss induced by cancer treatment and its management Eur J Cancer 34 2 1998 260-262
3. J. Pfeilschifter I.J. Diel Osteoporosis due to cancer treatment: pathogenesis and management J Clin Oncol 18 7 2000 1570-1593
4. P.D. Miller Bisphosphonates for the prevention and treatment of corticosteroid-induced osteoporosis Osteoporos Int 12 Suppl 3 2001 S3-S10
5. J.S. Finkelstein Osteoporosis In: L. Goldman D. Ausiello J.C. Bennet R.L. Cecil Cecil textbook of medicine 22nd ed. 2004 WB Saunders Company Philadelphia 656 1125 ills
6. I.R. Reid J.P. Brown P. Burckhardt Z. Horowitz P. Richardson U. Trechsel et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density N Engl J Med 346 9 2002 653-661
7. M.F. Townsend W.H. Sanders R.O. Northway S.D. Graham Jr. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma Cancer 79 3 1997 545-550
8. T. Hatano Y. Oishi A. Furuta S. Iwamuro K. Tashiro Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer BJU Int 86 4 2000 449-452
9. M.G. Oefelein V. Ricchuiti W. Conrad A. Seftel D. Bodner H. Goldman et al. Skeletal fracture associated with androgen suppression induced osteoporosis: The clinical incidence and risk factors for patients with prostate cancer J Urol 166 5 2001 1724-1728
10. WHO Scientific Group on the Burden of Musculoskeletal Conditions at the Start of the New Millennium. The burden of musculoskeletal conditions at the start of the new millennium. World Health Organ Tech Rep Ser 2003;919:i-x, 1-218, back cover.
11. A. Howell J. Cuzick M. Baum A. Buzdar M. Dowsett J.F. Forbes et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 9453 2005 60-62
12. Thürlimann B. Primary therapy of early breast cancer. In: 9th International Conference. January 26-29, 2005, St. Gallen, Switzerland. Abstracts. Breast 2005;14 Suppl 1:S1-56.
13. R.C. Coombes E. Hall L.J. Gibson R. Paridaens J. Jassem T. Delozier et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 11 2004 1081-1092
14. Goss PE. NCIC CTG MA.17 Final analysis of updated data. A placebo-controlled trial of letrozole following tamoxifen as adjuvant therapy in postmenopausal women with early stage breast cancer. In: 2004 ASCO Annual Meeting. Best of Oncology/Society Abstracts; 2004. Available from: http://www.asco.org/ac/.
15. Jakesz R, Kaufmann M, Gnant M, Jonat W, Mittlboeck M, Greil R, et al. Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results from 3123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. Breast Cancer Res Treat 2004;88 Suppl 1(Abstracts of the 27th Annual San Antonio Breast Cancer Symposium. December 8-11, 2004, San Antonio, TX, USA):S7, Abstract 2.
16. Z. Chen M. Maricic T.L. Bassford C. Ritenbaugh A.M. Lopez M.S. Leboff et al.Increased fracture risk among breast cancer survivors - results from the women's health initiative J Bone Miner Res 18 Suppl 2 2003 S2-S463
17. J.A. Kanis E.V. McCloskey T. Powles A.H. Paterson S. Ashley T. Spector A high incidence of vertebral fracture in women with breast cancer Br J Cancer 79 7-8 1999 1179-1181
18. S. Eriksson A. Eriksson R. Stege K. Carlstrom Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens Calcif Tissue Int 57 2 1995 97-99
19. J.F. Maillefert J. Sibilia F. Michel C. Saussine R.M. Javier C. Tavernier Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma J Urol 161 4 1999 1219-1222
20. H.W. Daniell S.R. Dunn D.W. Ferguson G. Lomas Z. Niazi P.T. Stratte Progressive osteoporosis during androgen deprivation therapy for prostate cancer J Urol 163 1 2000 181-186
21. A. Berruti L. Dogliotti C. Terrone S. Cerutti G. Isaia R. Tarabuzzi et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy J Urol 167 6 2002 2361-2367
22. V.B. Shahinian Y.F. Kuo J.L. Freeman J.S. Goodwin Risk of fracture after androgen deprivation for prostate cancer N Engl J Med 352 2 2005 154-164
23. B.E. Hillner J.N. Ingle J.R. Berenson N.A. Janjan K.S. Albain A. Lipton et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel J Clin Oncol 18 6 2000 1378-1391
24. B.E. Hillner J.N. Ingle R.T. Chlebowski J. Gralow G.C. Yee N.A. Janjan et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer J Clin Oncol 21 21 2003 4042-4057
25. E.P. Winer C. Hudis H.J. Burstein et al.] American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004 J Clin Oncol 23 8 2005 1609-1610
26. P.D. Delmas R. Balena E. Confravreux C. Hardouin P. Hardy A. Bremond Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double-blind, placebo-controlled study J Clin Oncol 15 3 1997 955-962
27. T. Diamond J. Campbell C. Bryant W. Lynch The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: Longitudinal evaluation and response to intermittent cyclic etidronate therapy Cancer 83 8 1998 1561-1566
28. T.H. Diamond J. Winters A. Smith P. De Souza J.H. Kersley W.J. Lynch The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: A double blind, randomized, placebo-controlled crossover study Cancer 92 6 2001 1444-1450
29. M.R. Smith F.J. McGovern A.L. Zietman M.A. Fallon D.L. Hayden D.A. Schoenfeld et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer N Engl J Med 345 13 2001 948-955
30. T. Saarto C. Blomqvist M. Valimaki P. Makela S. Sarna I. Elomaa Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens Br J Cancer 75 4 1997 602-605
31. Gnant M, Jakesz R, Mlineritsch B, Luschin-Ebengreuth G, Schmid M, Menzel C, et al. Zoledronic acid effectively counteracts cancer treatment induced bone loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole versus goserelin plus tamoxifen - bone density subprotocol results of a randomized multicenter trial (ABCSG-12). In: San Antonio Breast Cancer Symposium. San Antonio, TX; 2004.
32. J.Y. Reginster Y. Henrotin C. Christiansen E. Gamwell-Henriksen O. Bruyere J. Collette et al. Bone resorption in post-menopausal women with normal and low BMD assessed with biochemical markers specific for telopeptide derived degradation products of collagen type I Calcif Tissue Int 69 3 2001 130-137
33. Brufsky A, Harker G, Beck T, Carroll R, Tan-Chiu E, Seidler C, et al. Zoledronic acid (ZA) for prevention of cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant Letrozole (Let): Preliminary results of the Z-FAST trial. In: San Antonio Breast Cancer Symposium. San Antonio, TX; 2004.
34. F. Saad C. Olsson C.C. Schulman Skeletal morbidity in men with prostate cancer: Quality-of-life considerations throughout the continuum of care Eur Urol 46 6 2004 731-739
35. R.W. Ross E.J. Small Osteoporosis in men treated with androgen deprivation therapy for prostate cancer J Urol 167 5 2002 1952-1956
36. C. Magno G. Anastasi N. Morabito A. Gaudio D. Maisano F. Franchina et al. Preventing bone loss during androgen deprivation therapy for prostate cancer: Early experience with neridronate Eur Urol 47 5 2005 575-580
37. M.R. Smith J. Eastham D.M. Gleason D. Shasha S. Tchekmedyian N. Zinner Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer J Urol 169 6 2003 2008-2012
38. Jaschke A, Bastert G, Solomayer EF, Costa S, Schuetz F, Diel IJ. Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow - a longtime follow-up. J Clin Oncol 2004;22 (14S, 2004 ASCO Annual Meeting Proceedings, Post-Meeting Edition): Abstract 529.
39. Powles T, McCloskey E, Kurkilahti M. Oral clodronate for adjuvant treatment of operable breast cancer: Results of a randomized, double-blind, placebo-controlled multicenter trial. J Clin Oncol 2004;22 (14S, 2004 ASCO Annual Meeting Proceedings, Post-Meeting Edition): Abstract 528.
40. Saarto T, Vehmanen L, Blomqvist C, Elomaa I. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. J Clin Oncol 2004;22(14S, 2004 ASCO Annual Meeting Proceedings, Post-Meeting Edition): Abstract 527.
41. Clézardin P. Anti-tumor activity of Zoledronic acid. Cancer Treat Rev 2005;31(this issue):S1-S8.
42. Study Team EAU CRO. ZEUS study: Effectiveness of Zometa® treatment for the prevention of bone metastases in high risk prostate cancer patients. Eur Urol Today 2004;16(4):6.
43. J.P. Brown R.G. Josse 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada Can Med Assoc J 167 10 Suppl 2002 S1-S34
44. D.A. Loblaw D.S. Mendelson J.A. Talcott K.S. Virgo M.R. Somerfield E. Ben-Josef et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer J Clin Oncol 22 14 2004 2927-2941